VentriNova, a regenerative medicine company with a novel gene therapy product, has announced that the journal Science Translational Medicine has published the results of a preclinical study demonstrating the ability of VN-100 to regenerate heart muscle in large animals following a heart attack. The research was led by Dr. Hina Chaudhry, founder of VentriNova and Director of Cardiovascular Regenerative Medicine at Icahn School of Medicine at Mount Sinai.

More...